Vertex Pharmaceuticals price target raised to $540 from $522 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $540 from $522 and keeps a Buy rating on the ...
Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...
Vertex Pharmaceuticals' SWOT analysis: biotech giant's stock faces growth challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
Can new drug promise pain relief without peril?
The U.S. Food and Drug Administration has approved a novel prescription pain medication that targets sodium channels involved ...
STAT3d
The first shot taken at Medicaid, and Optum’s wellness visit ad
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
Vertex Pharmaceuticals: Strong Buy Rating Driven by Journavx Approval and Market Expansion Opportunities
Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and ...
FDA Approves New Non-Opioid Painkiller, Journavx: 'No Addiction Potential'
A participant in the drug trial for Journavx said it eliminated her pain without making her feel loopy or nauseous ...
RFK Jr. fields pharma questions on Day Two
After two days of making his case to Senate committees, Robert F. Kennedy Jr.’s bid to lead federal health agencies still ...
Wall Street Journal6d
Vertex Pharmaceuticals Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Associated Press on MSN6d
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...
BioPharma Dive13d
The biopharma industry outlook on 2025: Uncertainty and change
The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as threats ...